Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Legend Biotech Corporation - American Depositary Shares
(NQ:
LEGN
)
28.12
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corporation - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
September 27, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
↗
September 27, 2024
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma.
Via
Investor's Business Daily
Where Legend Biotech Stands With Analysts
↗
September 27, 2024
Via
Benzinga
Peering Into Legend Biotech's Recent Short Interest
↗
September 06, 2024
Via
Benzinga
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
↗
August 28, 2024
Via
Benzinga
Looking Into Legend Biotech's Recent Short Interest
↗
August 16, 2024
Via
Benzinga
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
↗
August 12, 2024
Via
Benzinga
The Latest Analyst Ratings For Legend Biotech
↗
July 15, 2024
Via
Benzinga
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 20, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
↗
August 09, 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
August 09, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
August 08, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Assessing Legend Biotech: Insights From 15 Financial Analysts
↗
June 21, 2024
Via
Benzinga
Unveiling 18 Analyst Insights On Legend Biotech
↗
June 04, 2024
Via
Benzinga
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
↗
May 14, 2024
Via
Benzinga
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
↗
August 01, 2024
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its...
Via
Benzinga
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
July 26, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
↗
July 21, 2024
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your...
Via
Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
↗
July 20, 2024
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal.
Via
Talk Markets
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
↗
July 18, 2024
Via
Benzinga
CPI Data Sparks Rally in Biotech Stocks
July 15, 2024
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.
Via
MarketBeat
Topics
ETFs
Economy
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
July 10, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
↗
July 02, 2024
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of...
Via
Benzinga
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
July 02, 2024
CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
↗
June 17, 2024
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product.
Via
Benzinga
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
↗
June 09, 2024
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.
Via
Benzinga
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
June 03, 2024
From
Legend Biotech
Via
Business Wire
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
May 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
↗
May 13, 2024
In the last three months, IBRX outperformed NVDA by over 3x.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
